LYEL vs. AMLX, PHAT, AKBA, AVXL, IMNM, IOVA, AVBP, TSHA, NAGE, and DNTH
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Amylyx Pharmaceuticals (AMLX), Phathom Pharmaceuticals (PHAT), Akebia Therapeutics (AKBA), Anavex Life Sciences (AVXL), Immunome (IMNM), Iovance Biotherapeutics (IOVA), ArriVent BioPharma (AVBP), Taysha Gene Therapies (TSHA), Niagen Bioscience (NAGE), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry.
Lyell Immunopharma vs. Its Competitors
Lyell Immunopharma (NASDAQ:LYEL) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.
In the previous week, Amylyx Pharmaceuticals had 9 more articles in the media than Lyell Immunopharma. MarketBeat recorded 12 mentions for Amylyx Pharmaceuticals and 3 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.79 beat Amylyx Pharmaceuticals' score of 1.03 indicating that Lyell Immunopharma is being referred to more favorably in the media.
Amylyx Pharmaceuticals has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -552,328.31%. Amylyx Pharmaceuticals' return on equity of -82.48% beat Lyell Immunopharma's return on equity.
Lyell Immunopharma currently has a consensus price target of $15.00, indicating a potential upside of 14.24%. Amylyx Pharmaceuticals has a consensus price target of $13.25, indicating a potential upside of 11.81%. Given Lyell Immunopharma's higher possible upside, equities analysts plainly believe Lyell Immunopharma is more favorable than Amylyx Pharmaceuticals.
66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 22.3% of Lyell Immunopharma shares are owned by insiders. Comparatively, 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Amylyx Pharmaceuticals has higher revenue and earnings than Lyell Immunopharma. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Lyell Immunopharma has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.45, meaning that its share price is 145% less volatile than the S&P 500.
Summary
Amylyx Pharmaceuticals beats Lyell Immunopharma on 10 of the 17 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
This page (NASDAQ:LYEL) was last updated on 9/16/2025 by MarketBeat.com Staff
Free LYEL Stock Alerts